Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Jun 24, 2015	Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis Second Phase 2 Trial Demonstrates Effectiveness of Intranasal Metoclopramide Spray	View HTML Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 18.8 KB
Toggle Summary May 14, 2015	Evoke Pharma Reports First Quarter 2015 Results Company Begins Preparation for Commercialization of EVK-001	View HTML Evoke Pharma Reports First Quarter 2015 Results 26.3 KB
Toggle Summary Apr 30, 2015	Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2015 Financial Results SOLANA BEACH, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter of 2015 on Thursday, May 14, 2015,	View HTML Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2015 Financial Results 11.8 KB
Toggle Summary Apr 14, 2015	Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001 Manufacturing Program Includes Three Year Registration Stability Data	View HTML Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001 17 KB
Toggle Summary Apr 09, 2015	Evoke Pharma Granted European Union Formulation Patent for EVK-001 SOLANA BEACH, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the European Patent Office has granted the Company European Union (EU) patent no.	View HTML Evoke Pharma Granted European Union Formulation Patent for EVK-001 14.9 KB
Toggle Summary Mar 04, 2015	Evoke Pharma to Present at the 27th Annual ROTH Conference SOLANA BEACH, Calif. , March 4, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, March 11, 2015 at 10:00AM PT at the 27 th Annual ROTH Conference .	View HTML Evoke Pharma to Present at the 27th Annual ROTH Conference 25.4 KB
Toggle Summary Mar 04, 2015	Evoke Pharma Reports Fourth Quarter and Year End 2014 Results SOLANA BEACH, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2014.	View HTML Evoke Pharma Reports Fourth Quarter and Year End 2014 Results 25.4 KB
Toggle Summary Feb 19, 2015	Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results SOLANA BEACH, Calif. , Feb. 19, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the fourth quarter of 2014 on Wednesday, March 4, 2015	View HTML Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results 12.4 KB
Toggle Summary Feb 02, 2015	Evoke Pharma Outlines Progress on Clinical Program SOLANA BEACH, Calif. , Feb. 2, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today provided an update on its clinical program for EVK-001, its novel metoclopramide nasal spray for the relief of	View HTML Evoke Pharma Outlines Progress on Clinical Program 16.3 KB
Toggle Summary Dec 02, 2014	Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study SOLANA BEACH, Calif. , Dec. 2, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced results from an electrocardiogram (ECG) study that assessed the potential of metoclopramide nasal	View HTML Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study 16 KB